Department of Surgery, St Thomas' Hospital, King's College London, London, UK; Department of Surgery, Royal Marsden Hospital, King's College London, London, UK; Gastrointestinal Cancer, Division of Cancer Studies, King's College London, London, UK; Unit of Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Br J Surg. 2014 Apr;101(5):511-7. doi: 10.1002/bjs.9456. Epub 2014 Feb 24.
The optimal surgical approach to tumours of the oesophagus and oesophagogastric junction remains controversial. The principal randomized trial comparing transhiatal (THO) and transthoracic (TTO) oesophagectomy showed no survival difference, but suggested that some subgroups of patients may benefit from the more extended lymphadenectomy typically conducted with TTO.
This was a cohort study based on two prospectively created databases. Short- and long-term outcomes for patients undergoing THO and TTO were compared. The primary outcome measure was overall survival, with secondary outcomes including time to recurrence and patterns of disease relapse. A Cox proportional hazards model provided hazard ratios (HRs) and 95 per cent confidence intervals (c.i.), with adjustments for age, tumour stage, tumour grade, response to chemotherapy and lymphovascular invasion.
Of 664 included patients (263 THO, 401 TTO), the distributions of age, sex and histological subtype were similar between the groups. In-hospital mortality (1·1 versus 3·2 per cent for THO and TTO respectively; P = 0·110) and in-hospital stay (14 versus 17 days respectively; P < 0·001) favoured THO. In the adjusted model, there was no difference in overall survival (HR 1·07, 95 per cent c.i. 0·84 to 1·36) or time to tumour recurrence (HR 0·99, 0·76 to 1·29) between the two operations. Local tumour recurrence patterns were similar (22·8 versus 24·4 per cent for THO and TTO respectively). No subgroup could be identified of patients who had benefited from more radical surgery on the basis of tumour location or stage.
There was no difference in survival or tumour recurrence for TTO and THO.
食管和食管胃交界部肿瘤的最佳手术方法仍存在争议。比较经胸(TTO)和经胸(THO)食管切除术的主要随机试验表明,两种手术方法在生存率上没有差异,但提示某些亚组患者可能受益于 TTO 中进行的更广泛的淋巴结清扫。
这是一项基于两个前瞻性数据库的队列研究。比较了 THO 和 TTO 患者的短期和长期结果。主要观察指标是总生存率,次要观察指标包括复发时间和疾病复发模式。Cox 比例风险模型提供了风险比(HR)和 95%置信区间(c.i.),并根据年龄、肿瘤分期、肿瘤分级、化疗反应和淋巴血管侵犯进行了调整。
在纳入的 664 例患者中(THO 组 263 例,TTO 组 401 例),两组的年龄、性别和组织学亚型分布相似。THO 组的住院死亡率(1.1%对 TTO 组的 3.2%;P=0.110)和住院时间(分别为 14 天和 17 天;P<0.001)均优于 TTO 组。在调整后的模型中,两种手术方法在总生存率(HR 1.07,95%c.i.0.84 至 1.36)或肿瘤复发时间(HR 0.99,0.76 至 1.29)方面无差异。局部肿瘤复发模式相似(THO 组为 22.8%,TTO 组为 24.4%)。基于肿瘤位置或分期,未确定任何亚组患者从更激进的手术中获益。
TTO 和 THO 的生存率和肿瘤复发率无差异。